Daniel Ramsbeck

Dr. Daniel Ramsbeck

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DRDaniel Ramsbeck
Daniel Ramsbeck
MBMirko Buchholz
Mirko Buchholz
BKBirgit Koch
Birgit Koch
LBLivia Böhme
Livia Böhme
THTorsten Hoffmann
Torsten Hoffmann
UHUlrich Heiser
Ulrich Heiser

29 September 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
DSDagmar Schlenzig
Dagmar Schlenzig
HCHolger Cynis
Holger Cynis
MHMaike Hartlage-Rübsamen
Maike Hartlage-Rübsamen
UZUlrike Zeitschel
Ulrike Zeitschel
KMKatja Menge
Katja Menge
HDHans-Ulrich Demuth
Hans-Ulrich Demuth
The formation of amyloid-β (Aβ) peptides is causally involved in the development of Alzheimer’s disease (AD). A significant proportion of deposited Aβ is N-terminally truncated and modified at the N-terminus by a pGlu-residue (pGlu-Aβ). These forms show enhanced neurotoxicity compared to full-length Aβ. Although the truncation may occur by aminopeptidases after formation of Aβ, recently discovered processing pathways of amyloid-β protein precursor (AβPP) by proteases such as meprin β may also be involved. Here, we assessed a role of meprin β in forming Aβ 3 -40/42 , which is the precursor of pGlu-Aβ 3 -40/42 generated by glutaminyl cyclase (QC). Similar to QC, meprin β mRNA is significantly upregulated in postmortem brain from AD patients. A histochemical analysis supports the presence of meprin β in neurons and astrocytes in the vicinity of pGlu-Aβ containing deposits. Cleavage of AβPP-derived peptides by meprin β in vitro results in peptides Aβ 1 -x , Aβ 2 -x , and Aβ 3 -x . The formation of N-truncated Aβ by meprin β was also corroborated in cell culture. A subset of the generated peptides was converted into pGlu-Aβ 3 -40 by an addition of glutaminyl cyclase, supporting the preceding formation of Aβ 3 -40 . Further analysis of the meprin β cleavage revealed a yet unknown dipeptidyl-peptidase–like activity specific for the N-terminus of Aβ 1 -x . Thus, our data suggest that meprin β contributes to the formation of N-truncated Aβ by endopeptidase and exopeptidase activity to generate the substrate for QC-catalyzed pGlu-Aβ formation.

1 June 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DRDaniel Ramsbeck
Daniel Ramsbeck
AHAntje Hamann
Antje Hamann
DSDagmar Schlenzig
Dagmar Schlenzig
SSStephan Schilling
Stephan Schilling
MBMirko Buchholz
Mirko Buchholz

14 November 2020 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KGKathrin Gnoth
Kathrin Gnoth
APAnke Piechotta
Anke Piechotta
MKMartin Kleinschmidt
Martin Kleinschmidt
SKSandra Konrath
Sandra Konrath
MSMathias Schenk
Mathias Schenk
Stephan SchillingStephan Schilling
Stephan Schilling
Background: Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evidence suggests that post-translationally modified Aβ peptides might play a decisive role in onset and progression of AD and first clinical trials targeting such Aβ variants have been initiated. Modified Aβ represents a small fraction of deposited material in plaques compared to pan-Aβ epitopes, opening up pathways for tailored approaches of immunotherapy. Here, we generated the first monoclonal antibodies that recognizel-isoaspartate-modified Aβ (isoD7-Aβ) and tested a lead antibody molecule in 5xFAD mice.Methods: This work comprises a combination of chemical and biochemical techniques as well as behavioral analyses. Aβ peptides, containingl-isoaspartate at position 7, were chemically synthesized and used for immunization of mice and antibody screening methods. Biochemical methods included anti-isoD7-Aβ monoclonal antibody characterization by surface plasmon resonance, immunohistochemical staining of human and transgenic mouse brain, and the development and application of isoD7-Aβ ELISA as well as different non-modified Aβ ELISA. For antibody treatment studies, 12 mg/kg anti-isoD7-Aβ antibody K11_IgG2a was applied intraperitoneally to 5xFAD mice for 38 weeks. Treatment controls implemented were IgG2a isotype as negative and 3D6_IgG2a, the parent molecule of bapineuzumab, as positive control antibodies. Behavioral studies included elevated plus maze, pole test, and Morris water maze.Results: Our advanced antibody K11 showed a KDin the low nM range and > 400fold selectivity for isoD7-Aβ compared to other Aβ variants. By using this antibody, we demonstrated that formation of isoD7-Aβ may occur after formation of aggregates; hence, the presence of the isoD7-modification differentiates aged Aβ from newly formed peptides. Importantly, we also show that the Tottori mutation responsible for early-onset AD in a Japanese pedigree is characterized by massively accelerated formation of isoD7-Aβ in cell culture. The presence of isoD7-Aβ was verified by K11 in post mortem human cortex and 5xFAD mouse brain tissue. Passive immunization of 5xFAD mice resulted in a significant reduction of isoD7-Aβ and total Aβ in brain. Amelioration of cognitive impairment was demonstrated by Morris water maze, elevated plus maze, pole, and contextual fear conditioning tests. Interestingly, despite the lower abundance of the isoD7-Aβ epitope, the application of anti-isoD7-Aβ antibodies showed comparable treatment efficacy in terms of reduction of brain amyloid and spatial learning but did not result in an increase of plasma Aβ concentration as observed with 3D6 treatment.Conclusions: The present study demonstrates, for the first time, that the antibody-mediated targeting of isoD7-modified Aβ peptides leads to attenuation of AD-like amyloid pathology. In conjunction with previously published data on antibodies directed against pGlu-modified Aβ, the results highlight the crucial role of modified Aβ peptides in AD pathophysiology. Hence, the results also underscore the therapeutic potential of targeting modified amyloid species for defining tailored approaches in AD therapy.

25 April 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DRDaniel Ramsbeck
Daniel Ramsbeck
AHAntje Hamann
Antje Hamann
GRGeorg Richter
Georg Richter
DSDagmar Schlenzig
Dagmar Schlenzig
SGStefanie Geissler
Stefanie Geissler
MBMirko Buchholz
Mirko Buchholz

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NTNadine Taudte
Nadine Taudte
MLMiriam Linnert
Miriam Linnert
JRJens-Ulrich Rahfeld
Jens-Ulrich Rahfeld
APAnke Piechotta
Anke Piechotta
DRDaniel Ramsbeck
Daniel Ramsbeck
MSMilton T. Stubbs
Milton T. Stubbs
The development of a targeted therapy would significantly improve the treatment of periodontitis and its associated diseases including Alzheimer’s disease, rheumatoid arthritis, and cardiovascular diseases. Glutaminyl cyclases (QCs) from the oral pathogens Porphyromonas gingivalis, Tannerella forsythia, and Prevotella intermedia represent attractive target enzymes for small-molecule inhibitor development, as their action is likely to stabilize essential periplasmic and outer membrane proteins by N-terminal pyroglutamination. In contrast to other microbial QCs that utilize the so-called type I enzymes, these oral pathogens possess sequences corresponding to type II QCs, observed hitherto only in animals. However, whether differences between these bacteroidal QCs and animal QCs are sufficient to enable development of selective inhibitors is not clear. To learn more, we recombinantly expressed all three QCs. They exhibit comparable catalytic efficiencies and are inhibited by metal chelators. Crystal structures of the enzymes from P. gingivalis (PgQC) and T. forsythia (TfQC) reveal a tertiary structure composed of an eight-stranded β-sheet surrounded by seven α-helices, typical of animal type II QCs. In each case, an active site Zn ion is tetrahedrally coordinated by conserved residues. Nevertheless, significant differences to mammalian enzymes are found around the active site of the bacteroidal enzymes. Application of a PgQC-selective inhibitor described here for the first time results in growth inhibition of two P. gingivalis clinical isolates in a dose-dependent manner. The insights gained by these studies will assist in the development of highly specific small-molecule bacteroidal QC inhibitors, paving the way for alternative therapies against periodontitis and associated diseases.